Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
No clinical trials have been registered for primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma.
2 publications have been identified in PubMed for primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma. Research spans Case Report / Case Series (100%).
Li X (2025). [PMID: 40970874](https://pubmed.ncbi.nlm.nih.gov/40970874/). *The American Journal of dermatopathology*. [Case Report / Case Series]
Ufomadu P (2025). [PMID: 40291079](https://pubmed.ncbi.nlm.nih.gov/40291079/). *Proceedings (Baylor University. Medical Center)*. [Case Report / Case Series]
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 12:17 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma
Updated Feb 20, 2026
A case study highlights a pediatric patient with Crohn's disease who developed primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder associated with vedolizumab. This finding underscores the need for vigilance regarding potential lymphoproliferative disorders in biologic-naïve patients.